Skinvisible, Inc. (OTCQB: SKVI) is set for a business renaissance in the coming years.
Skinvisible, Inc. (OTCQB: SKVI) is set for a business renaissance in the coming years.
Marijuana Company of America (OTC: MCOA) is a distinctive corporation utilizing a strategic business structure within this burgeoning industry.
As one of Canada’s first licensed cannabis producers, ABcann is significantly ahead of the curve when it comes to production capacities.
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America.
Research and development company Skinvisible, Inc. (OTCQB: SKVI) has set its sights on the burgeoning global markets for skincare, dermatology and over-the-counter products.
Invisicare®, a proprietary topical drug delivery technology developed by Skinvisible, Inc. has a potentially wide range of applications in the cannabis market.
As Canada prepares for the legalization of recreational marijuana in July 2018, analysts are noting a shortage of supplies compared to expected demand for cannabis products.
The company’s most recent research and development focus continues to be on readying a line of cannabis-based products targeting Alzheimer’s disease.
With a portfolio of operating subsidiaries, partnerships and joint ventures, Marijuana Company of America (OTC: MCOA) offers investors broad diversification guided by experienced and savvy management.
Marijuana Company of America (OTC: MCOA) is a unique corporation with a strategic business structure that functions as an umbrella, bringing together a diverse portfolio of investments and joint ventures within the legal cannabis industry.
Investors interested in medicinal marijuana and/or Alzheimer’s treatments will find themselves looking at a global landscape of key players.
AV1 Group (OTC: AVOP) is building its focus of identifying, securing and monetizing companies with emerging growth potential.
With a market that’s expected to grow from $2 billion in 2020 to $50 billion in only nine years, according to Statista, biotechnology companies are increasingly focused on the development of proprietary systems and procedures to drive research and production of cannabinoid pharmaceuticals.
Marijuana Company of America, Inc. (OTC: MCOA) is building upon its vertically integrated business strategy by taking a unique approach to how companies within the industry position themselves in the marketplace.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed delivery technologies to improve absorption of bioactive compounds and intends to use that technology in the tea market.